The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC ...

The European drugs regulator said on Thursday its safety panel has confirmed suicidal thoughts as a side effect of ...

The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya vaccine after ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad ...

Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved ...

Key messagesGREG is a five-year, 26.2 million euros initiative that unites 29 partner organisations to advance Real-World ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

The inspection was conducted by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14 and it concluded with ...

Few areas of healthcare are as sensitive as cancer treatment. Each year, around 44,000 cancer tumours are diagnosed here.